Introduction
Several antigens including Factor VIII, CD31, CD36, Ulex Europeaus lectin and PAL-E have been used as endothelial cell markers in a vast number of publications. However, none of these markers are perfect, because they either do not stain all types of endothelia or are not specific for vasculature. PAL-E has been considered as a good marker, because it discriminates blood vessel endothelium from lymphatic endothelium and does not stain other cell types. [1] [2] [3] Despite the relatively wide use of PAL-E as an endothelial marker, its molecular identity has remained an enigma most likely due to the limited applicability of the antibody against the PAL-E molecule. However, a recent report suggests that the PAL-E antigen is a secreted form of vimentin. 4 The molecule defined by PAL-E is widely expressed on vasculature in different organs except in brain. However, its expression is induced in brain tumors simultaneously with the loss of the blood-brain barrier. 5 Expression of PAL-E antigen is also increased on endocardium of rejected human cardiac allografts. 6 PV-1 has been described as a glycoprotein associated to plasmalemmal vesicles (caveolae). It is a 60 kDa type II transmembrane protein which tends to form homodimers.
Its cellular localization in the rat has been carefully analyzed both at light and electron microscopic levels. 7, 8 However, the function of PV-1 has remained unknown. Expression of rat PV-1 is developmentally regulated in testis and it binds heparin. 9 The protein sequences of rat and mouse PV-1 have phosphorylation site(s) for casein kinase II, but this site is lacking in the human sequence. 10 The corresponding human sequence does not bear significant homology to any other known proteins and therefore, the sequence information has not helped in predicting the function of this molecule.
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Our original aim was to identify new endothelial molecules involved in leukocyte trafficking. For this purpose we raised monoclonal antibodies against small isolated vessels from the hilus of human lymph nodes. The expression pattern of one antibody showed striking specificity for endothelial cells and therefore, the antigen recognized by this antibody was selected for further characterization. Tryptic peptides and subsequent analyses of its cDNA showed homology of this antigen to rat PV-1 cDNA and a human cDNA designated FELS. On the other hand, the similarities in the staining patterns between our antibody and PAL-E led to the present studies elucidating the identity of the molecule recognized by PAL-E.
Materials and methods

Production of the monoclonal antibody
Balb/C mice were immunized by injecting into the footpads a suspension containing isolated hilar vessels from human lymph nodes and Freund's incomplete adjuvant in PBS three times with one-week intervals between injections. Three days after the last immunization the popliteal lymph nodes were collected and the isolated lymphocytes were fused with SP2/0 myeloma cells. The hybridoma supernatants were screened by immunohistochemistry using frozen sections of human tonsils. Hybridoma 174/2 was selected for further analyses because of its highly specific endothelial staining pattern.
Peptide and cDNA analyses
The molecule recognized by 174/2 antibody from human lymph node lysate was purified with CnBr-Sepharose 4B (Pharmacia) columns coupled to 174/2 antibody as described 11 and the eluted material was subjected to SDS-PAGE analysis and silver staining. We excised the specific band and reduced, alkylated and digested it with trypsin overnight at 
Results
Mice were immunized with isolated human vessels to produce anti-endothelial cell antibodies. When the hybridoma supernatants were in their first screen on human tonsils, 174/2 antibody showed exceptional specificity towards endothelial cells. 174/2 stained small and medium sized vessels on both venous and arterial side. This endothelial specificity held true in more extensive analyses involving peripheral lymph nodes, tonsil, skin, intestine, heart, kidney, appendix and liver. In contrast normal brains were virtually 174/2 negative (data not shown). show that the signal comes from the cytoplasm above the nucleus and no intra-nuclear localization of PV-1 can be seen (Figure 2k ).
To formally confirm that 174/2 recognizes the same molecule as PAL-E crossimmunoprecipitations were made from the CHO transfectants expressing PV-1/FELS.
PAL-E was able to deplete practically all 120 kDa protein (homodimer) detected by 174/2, whereas after depletion with 174/2 a very faint, lower molecular weight form of 85 kDa was still recognized by PAL-E (Figure 3a) . Most likely this lower molecular weight form represents a degradation product of the molecule that does not bear the epitope recognized by 174/2. To confirm that PAL-E and 174/2 recognize the same antigen also on endothelium in tissues, we first performed immunoblotting from tonsil lysate. Both 174/2 and PAL-E recognized a band of the same size in non-reduced sample, whereas PAL-E did not show any reactivity, when the sample was reduced (Figure 3b) . We further precleared lymphocyte-depleted tonsil tissue with beads coupled to 174/2, PAL-E or negative control antibody (3G6). 174/2 and PAL-E (but not the negative control antibody) During the preparation of this work the PAL-E antigen was reported to be a secreted form of vimentin on endothelium. 4 Tissue expression of PV-1 (PAL-E staining) and vimentin argues against them being the same molecule. To rule out the identification of PAL-E as vimentin, we stained PV-1 transfected CHO cells and mock controls with PAL-E and anti-vimentin antibodies. Anti-vimentin antibody nicely stained intracytoplasmic filaments of both PV-1 and mock transfected controls (data not shown).
In contrast, when not permeabilized no vimentin expression was seen on the surface of either of these cells (Figure 6a ). PAL-E antibody stained non-permeabilized PV-1 transfected cells, while the mock transfected cells remained completely negative ( Figure 6a ). To demonstrate that PAL-E does not recognize vimentin we depleted PV-1 positive HMEC-cell lysate with beads coupled to anti-vimentin antibody (V9), 174/2, PAL-E or negative control antibody. Only V9 was able to remove the reactivity of V9 when the depleted lysates were tested in immunoblotting (Figure 6b) . These results unambiguously demonstrate that PAL-E antigen is the same as PV-1 and not vimentin.
Discussion
In this work we have resolved the identity of the molecule recognized by PAL-E antibody. From a historical point of view it is interesting that PAL-E has been used so extensively and for such a long time as a marker molecule for vascular endothelium without knowing its molecular identity. One important reason for this is that the PAL-E antibody works only in limited applications. In contrast, the properties of the 174/2 antibody allow it to be used not only as a marker for endothelial cells but also in many other applications. Moreover, purification of the 174/2 antigen should facilitate the production of mAbs against this antigen that also work in formalin-fixed, paraffinembedded sections.
In a recent report PAL-E antigen was proposed to be a secreted form of vimentin. 4 There may be several reasons for the remarkable discrepancy between our 
